On our screens:Stocks with no debt
Is the price fair?
What INVA's price assumes
Innoviva, Inc. trades at 3.54× earnings against 31.5× for the median Biotechnology name, cheaper than its own group.
3.54
Trailing P/E · Biotechnology median 31.5 · cheaper than the typical name in its group
- Price / sales
- 4.70
Price / sales · as of 2026-Q1
- Free cash flow yield
- 7.6%
Free cash flow yield · Biotechnology median 2.4%
- Growth the price implies
- +0.02%
Growth the price implies · The price pays for +0.02% free cash flow growth a year for a decade; the business has delivered +0.60% a year over the last three.
Details›
- Price / book2026-Q1
- 1.47
- EV / EBIT2026-Q1
- 10.2
- EV / sales2026-Q1
- 3.88
- Healthcare median P/E362 names
- 29.9
- Biotechnology median P/E158 names
- 31.5
- Free cash flow, trailing twelve months
- $132M
- Market capitalisation
- $1.72B
- 3-year revenue growth
- +9.8%
- 3-year free cash flow growth
- +0.60%
| Method | Per share |
|---|---|
| What its own history would imply | not meaningful, 19.8× today against a 7.22× median |
| 52-week range | $16.67 – $24.24 |
| Today | $21.34 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Biotechnology
Ranks #54 of 143 by Smart Score